RBN013209

RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors[1][2][3].

Product Specifications

CAS Number

[2597933-17-8]

UNSPSC

12352005

Target

CD38; LAG-3; PD-1/PD-L1; Tim3

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rbn013209.html

Concentration

10mM

Purity

98.63

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COCCO[C@@H](CC1)CC[C@H]1NC(C2=C3C(C=CN3)=NC(N4C=CN=C4)=N2)=O

Molecular Formula

C19H24N6O3

Molecular Weight

384.43

References & Citations

[1]Laurie B. Schenkel, et al. Heterobicyclic amides as inhibitors of cd38. WO2021021986A1.|[2]Shambharkar, et al. Small molecule inhibitor of CD38 modulates its intra-and extracellular functions leading to antitumor activity. Cancer Research 81.13_Supplement (2021) : 1344-1344.|[3]Huang Y, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024 Feb 20;5 (2) :101400.